Plain-English translation of NCT07154706 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called can help prevent lung cancer from returning in patients who have already had surgery to remove their tumor. The study compares this medication to a placebo (a pill with no active ingredient) in people with a specific type of early-stage lung cancer that has a ROS1 gene change. The goal is to find out if this treatment can keep the cancer from coming back.
After surgery for early-stage lung cancer, some patients experience cancer recurrence even after complete tumor removal. This trial is testing whether this medication might reduce that risk and improve long-term outcomes for people with this specific type of lung cancer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication or a placebo—neither you nor your doctors will know which one you're taking. You will take a daily pill for about 3 years and have regular visits with your medical team to check on your health and watch for any side effects. The study will monitor whether your cancer returns and how well you're doing overall.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States